Photo Credit: iStock.com/KJPargeter
Bimekizumab showed sustained symptom improvement and consistent safety in patients with psoriatic arthritis, including TNFi-IR and bDMARD-naïve groups.
Bimekizumab improved symptoms and was well tolerated up to two years in patients with psoriatic arthritis (PsA), according to an article published in Rheumatology and Therapy.
The paper reported results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) trials and their open-label extension, BE VITAL (NCT04009499). BE OPTIMAL included patients not previously treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve), and BE COMPLETE included patients with an inadequate response to tumor necrosis factor inhibitors (TNFi-IR).
BE VITAL was an open-label extension through week 104 that included patients who completed week 52 of BE OPTIMAL and patients who completed week 16 of BE COMPLETE.
“Of patients who received bimekizumab from the start of the study, the proportion of patients achieving improvements in joint, skin, and other disease symptoms was similar from year 1 to year 2,” wrote corresponding author Philip J. Mease, MD, and colleagues.
Responses were similar in both groups of patients, according to the summary. In joint outcomes, rates of American College of Rheumatology 50% improvement (ACR50) with bimekizumab were 54.3% in year 1 and 51.5% in year 2 for patients who were bDMARD-naïve. In patients with TNFi-IR, rates of ACR50 with bimekizumab were 51.7% in year 1 and 50.6% in year 2.
Additionally, Psoriasis Area and Severity Index 100% (PASI100) improvement rates were 60.4% in year 1 and 59.4% in year 2 in patients who were bDMARD-naïve, and 65.9% in year 1 and 63.1% in year 2 in patients with TNFi-IR. Minimal disease activity in at least 5 of 7 measures (swollen joints, tender joints, skin, physical function, pain, global assessment, and enthesitis) occurred in 54.8% of bDMARD-naïve patients in year 1 and 52.4% in year 2, and in 46.4% of TNFi-IR patients in year 1 and 44.9% in year 2.
Side effects and discontinuations because of side effects were comparable in year 1 and year 2 of the trials.
“Overall, bimekizumab was well tolerated up to 2 years,” the authors wrote, “and the safety of the treatment was similar to what was seen in previous phase 2b and 3 studies of bimekizumab in patients with PsA.”
UCB funded the research.
Create Post
Twitter/X Preview
Logout